IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Anticipated Classification Of this Application: Class Subclass	Prior Application: Exam'r: Arun K. Chakrabarti, Ph.D. Prior Group Art Unit: <u>1634</u>	Attorney's Docket No.: Enz-52(C)(D3)
FILED BY EXPRESS MAIL		OTG
Mail Stop Patent Application Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450		17548 U.S.
Sir:		
CONTINUATION-IN-PART aps 1.53(b), of pending prior app 1.53(b), of pending prior app 1.53(b), of pending prior app 1.54(b), of	X CONTINUATION DIVISION oplication under 37 CFR §1.53(b) oplication Serial No. 10/206,031 filed agelhardt, et al. oventor(s) CESS, CONSTRUCT AND CONJUGATION Title of Invention is a copy of the prior application, as vit or declaration verifying it as a true tity status was previously established on and is still applicable.	X 37 CFR d on June 6, 2003 ATE PIES originally filed and e copy.
Deposit D I hereby c herein are Service "E under 37 addressed Trademark Ronald	EXPRESS MAIL CERTIFICATE Mail" Label No. ER458165976US ate November 18, 2003 ertify that this paper and the attachments being deposited with the United States Postal express Mail Post Office to Addressee" service CFR 1.10 on the date indicated above and is to the Commissioner of Patents and as, Washington DC 20231. NOV 18 2003 I.C. Fedus Date 1.32,567	

Engelhardt, et al.

Serial No.: Not Yet Assigned

(Continuation of S. N. 10/206,031, filed June 6, 2003)

Filed: Herewith

Page: 2 (Request for a Continuation Application Under 37 C.F.R. §1.53(b) -

November 18, 2003)

3. X The filing fee is calculated as follows:

CLAIMS AS FILED, LESS ANY CLAIMS CANCELLED BY AMENDMENT									
					RA	TE		F	EE
	Number Filed		Number Extra		Small Entity	Other Entity		Small Entity	Other Entity
Total Claims	33	=	13	x	\$ 9	\$ N/A	=	\$117	\$
Independent Claims	3	=	0	x	\$ 43	\$ N/A	=	\$ O	\$
Multiple Dependent Claims Presented:YesXNo				\$135	\$270		\$	\$	
* If the difference in Col. 1 is less than zero, enter "0" in Col.2				BASIC FEE		\$385	\$		
				TOTAL FEE		\$502	\$		

4.	X	The Commissioner is hereby authorized to charge payment of the filing fee as well as the following fees associated with this application or to credit any overpayment to Deposit Account No 05-1135. A duplicate copy of this sheet is enclosed.			
	X	Any addition	nal filing fees required under 37 CFR §1.16.		
	X	Any patent	application processing fees under 37 CFR §1.17.		
5.	<u>X</u>	The Commissioner is hereby authorized to charge pay the following fees during the pendency of this application credit any overpayment to Deposit Account No. 05-1 duplicate copy of this sheet is enclosed.			
		X	Any patent application processing fees under 37 CFR §1.17.		
			The issue fee set in 37 CFR §1.18 at or before mailing of the Notice of Allowance, pursuant to 37 CFR §1.311(b).		

Engelhardt, et al.

Serial No.: Not Yet Assigned

(Continuation of S. N. 10/206,031, filed June 6, 2003)

Filed: Herewith

Page: 3 (Request for a Continuation Application Under 37 C.F.R. §1.53(b) -

November 18, 2003)

		Any filing fees under 37 CFR §1.16 for presentation of extra claims.
6.		A check in the amount of \$ is enclosed.
7.	<u>X</u>	Cancel claims 2-90
8.	X	Amend the specification by inserting before the first line of the sentence: This is a X continuation, divisional of U.S. Patent Application Serial No. 10/260,031, filed on June 6, 2003, which is a continuation of U.S. Patent Application Serial No. 09/260,031, filed on April 16, 1999, now abandoned. Serial No. 09/260,031 is a divisional of Serial No. 08/182,621, filed on January 13, 1994, also abandoned
9.		Transfer the drawings from the prior application.
10.	X	Informal X Formal drawings are enclosed.
11.		Abandon said prior application as of the filing date accorded this application. A duplicate copy of this sheet is enclosed for filing in the prior application file.
12.		Priority of application Serial No filed on is claimed under 35 U.S.C. §119 The certified copy of the priority application has been filed in prior application Serial No , filed
13.	X	The prior application is assigned of record to Enzo Diagnostics, Inc., c/o Enzo Biochem, Inc., 527 Madison Avenue, New York, New York 10022. A copy of the Assignment is enclosed.
14.	X	A preliminary amendment is enclosed.

Page:	4	(Request	for a Continu November 1	uation Application Under 37 C.F.R. §1.53(b) - 8, 2003)			
15.		X	The power of attorney in the prior application is to: Ronald C. Fedus, Reg. No. 32,567.				
			(a) X	The power appears in the original papers in the prior application.			
			(b)	Since the power does not appear in the original papers, a copy of the power in the prior application is enclosed.			
			(c)	A copy of a new substitute power of attorney is enclosed.			
			(d)	A copy of a new Associate Power of Attorney is enclosed.			
			(e) <u>X</u>	Address all future communications to: (May only be completed by applicant, or attorney or agent of record.)			
				Ronald C. Fedus, Esq. Enzo Life Sciences, Inc. c/o Enzo Biochem, Inc. 527 Madison Avenue (9th Floor) New York, New York 10022			
16.		X	Oath or Dec	laration			
	ė		(a)	Newly executed (original or copy)			
			(b) <u>X</u>	Copy from a prior application (37 CFR 1.63(d))			
			(c) <u>X</u>	With Power of Attorney			
			(D)	Without Power of Attorney			

(Continuation of S. N. 10/206,031, filed June 6, 2003)

Engelhardt, et al.

Filed: Herewith

Serial No.: Not Yet Assigned

Engelhardt, et al. Serial No.: Not Yet Assigned (Continuation of S. N. 10/206,031, filed June 6, 2003) Filed: Herewith Page: 5 (Request for a Continuation Application Under 37 C.F.R. §1.53(b) -November 18, 2003) 17. I hereby verify that the attached papers are a true copy of prior application Serial No. 10/206,031, filed on June 6, 2003. The undersigned declares further that all statements made herein of his own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issuing thereon. Respectfully submitted, November 18, 2003 Date Ronald C. Fedus Registration No. 32,567 Attorney for Applicants Inventor(s) Assignee of Complete Interest Attorney or Agent of Record

Filed under 37 CFR § 1.34(a)

Address of Signator: Enzo Life Sciences, Inc. c/o Enzo Biochem, Inc. 527 Madison Avenue (9th Floor) New York, NY 10022-4304